A Phase 1 interventional study of Naloxone and Mucosal atomization device and syringe in Opioid-use Disorder, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-09.
Sponsored by National Institute on Drug Abuse (NIDA) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA) — 4 open to participants now, 4 under way, none of them phase 3. Opioid-Related Disorders · National Institute on Drug Abuse (NIDA).
Among the 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA), this one is the 20th largest by enrollment of the 70 interventional ones that give a count, is the only one that started in 2018, is one of 22 in phase 1, and was the 68th registered.
1,475 studies on the registry are indexed under Opioid-Related Disorders; 292 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA) are open now, in 1 country. Recruiting first, the newest first:
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–60 · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 21–60 · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 212 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 75 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 38 · Phase 3 2 · Phase 4 1
First in 1989; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 63 across 1,169 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 4 across the 70 interventional studies, 67 across the 6 observational. Of the 71 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute on Drug Abuse (NIDA) is the lead sponsor of 393 studies on the registry; 19 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
3 of the studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06808932National Institute on Drug Abuse (NIDA)VK4-116 Phase I Study With Food-Effect | 2027-07 |
| NCT07204171National Institute on Drug Abuse (NIDA)Phase 1 Study of Oral MG001 | 2027-10 |
| NCT03745339National Institute on Drug Abuse (NIDA)Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intranasal (IN) naloxone administration is an effective alternative to intravenous (IV) or intramuscular (IM) naloxone by emergency medical services for opioid overdoses and has been used successfully for this purpose as reported in clinical observational studies and a randomized controlled trial. Most of the published clinical studies concerning IN administration used an improvised kit of 2 mg naloxone/2 mL saline and a mucosal atomizer device (MAD), which is not FDA-approved for this indication. Pharmacokinetic (PK) data using these kits is not available in the published literature. This study is designed to determine the PK of naloxone following one and two IN administrations using the improvised kits compared to 2 and 4 mg delivered IN using the FDA-approved Narcan nasal spray device and 2 mg administered IM using the Evzio autoinjector.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
Drug: Naloxone · Device: Mucosal atomization device and syringe
Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
Drug: Naloxone · Device: Mucosal atomization device and syringe
One Intranasal administration of 2 mg naloxone using Narcan nasal spray
Drug: Naloxone · Device: Narcan
One Intranasal administration of 4 mg naloxone using Narcan nasal spray
Drug: Naloxone · Device: Narcan
One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
Drug: Naloxone · Device: Intramuscular Auto Injector
Comparing pharmacokinetics of naloxone
Injection
Nasal Spray
Intramuscular injection
Also known as: Evzio
Pharmacokinetic parameters of naloxone
Maximum plasma concentration, time of maximum observed concentration and area under the concentration-time curve
Time frame: 11 days
Safety Assessments
Number of participants with AEs, vital signs, ECG, laboratory changes and nasal irritation following the administration of naloxone.
Time frame: 16 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Feb 2018, 1 month.
Of 54 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 1 month is below that.
Counting every sponsor, half of 78 studies reached it within 19 months; a quarter within 9 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute on Drug Abuse (NIDA) →